XTSE
CPH
Market cap248mUSD
Jun 06, Last price
13.25CAD
1D
8.08%
1Q
17.36%
Jan 2017
170.41%
IPO
413.57%
Name
Cipher Pharmaceuticals Inc
Chart & Performance
Profile
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 33,363 57.66% | 21,162 2.36% | 20,675 -5.78% | |||||||
Cost of revenue | 21,498 | 9,902 | 9,625 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 11,865 | 11,260 | 11,050 | |||||||
NOPBT Margin | 35.56% | 53.21% | 53.45% | |||||||
Operating Taxes | (8,590) | (7,702) | (15,157) | |||||||
Tax Rate | ||||||||||
NOPAT | 20,455 | 18,962 | 26,207 | |||||||
Net income | 11,545 -43.36% | 20,383 -23.48% | 26,636 243.34% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (176) | (5,559) | (1,988) | |||||||
BB yield | 0.05% | 3.95% | 0.48% | |||||||
Debt | ||||||||||
Debt current | 283 | 94 | 101 | |||||||
Long-term debt | 40,873 | 612 | 755 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 23,319 | (39,119) | (46,921) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 19,546 | 15,999 | 10,575 | |||||||
CAPEX | (44) | (21) | (81) | |||||||
Cash from investing activities | (80,044) | (144) | (81) | |||||||
Cash from financing activities | 39,296 | (5,244) | (1,914) | |||||||
FCF | 22,357 | 15,808 | 26,170 | |||||||
Balance | ||||||||||
Cash | 17,837 | 39,825 | 28,836 | |||||||
Long term investments | 18,941 | |||||||||
Excess cash | 16,169 | 38,767 | 46,743 | |||||||
Stockholders' equity | 95,818 | 74,765 | 58,722 | |||||||
Invested Capital | 126,752 | 42,106 | 12,861 | |||||||
ROIC | 24.23% | 68.99% | 428.37% | |||||||
ROCE | 8.30% | 13.92% | 18.54% | |||||||
EV | ||||||||||
Common stock shares outstanding | 24,568 | 25,422 | 107,486 | |||||||
Price | 14.32 158.48% | 5.54 44.27% | 3.84 116.95% | |||||||
Market cap | 351,820 149.80% | 140,839 -65.88% | 412,746 769.14% | |||||||
EV | 375,139 | 101,720 | 365,825 | |||||||
EBITDA | 15,882 | 12,487 | 12,039 | |||||||
EV/EBITDA | 23.62 | 8.15 | 30.39 | |||||||
Interest | 464 | |||||||||
Interest/NOPBT | 4.20% |